Archives

12 September 2016 MVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox® in Canada (Pickering, Canada and Victoria, Australia, 12 September 2016) Medical Developments International Limited (MDI) (ASX: MVP) is delighted to announce it has reached an exclusive distribution and licensing agreement with Purdue Pharma (Canada) for Penthrox® (Low-Dose Methoxyflurane) Inhaler in […]

9 September 2016 ASX ANNOUNCEMENT Penthrox receives regulatory approval in the UAE Medical Developments International Limited (ASX: MVP) is delighted to announce that it has received regulatory approval and the Marketing Authorisation (MA) for the sale of Penthrox in the United Arab Emirates (UAE). The CEO of MVP, Mr. Sharman said: “Penthrox has been supplied […]

6 September 2016 ASX ANNOUNCEMENT Licensing deal for Korea Medical Developments International Limited (MDI) (ASX: MVP) is delighted to announce it has reached agreement with BL&H Co Ltd (BL&H) for the exclusive distribution rights of Penthrox® in Korea. The transaction includes upfront and milestone payments of AUD $1.2 million and BL&H will manage the registration, […]

18 August 2016 ASX ANNOUNCEMENT FY16 Full Year Results For details relating to the full ASX Release, please click on the following link FY16 Full Year Results

12 August 2016 ASX ANNOUNCEMENT European Penthrox Update. Medical Developments International Limited (ASX: MVP) advises that the roll out and acceptance of Penthrox in the United Kingdom, Republic of Ireland and the EU is going to plan. CEO of Medical Developments, Mr. John Sharman said: “We have just received our first order from Mundipharma for […]

9 August 2016 ASX ANNOUNCEMENTS – USA Penthrox Update & USA Respiratory Update USA : Penthrox update Medical Developments International (ASX: MVP) advises it has received a written response to its meeting request by the Food & Drug Administration (FDA) in the United States of America.  On the basis of the FDA’s written response, MVP […]

9 August 2016 ASX ANNOUNCEMENTS – USA Penthrox Update & USA Respiratory Update USA : Penthrox update Medical Developments International (ASX: MVP) advises it has received a written response to its meeting request by the Food & Drug Administration (FDA) in the United States of America.  On the basis of the FDA’s written response, MVP […]

14 June 2016   ASX ANNOUNCEMENT   Licensing deal for Canada Medical Developments International Limited (ASX: MVP) is delighted to announce it has signed a Term Sheet with a significant pharmaceutical company to distribute Penthrox® in Canada. The Term Sheet includes upfront and milestone payments of CAD $3.0 million. For more details please click on […]

Bell Potter and Patersons has recently initiated coverage on Medical Developments International (ASX:MVP).  For a copy of the analyst’s report which has market analysis, buy recommendation and price target, please contact Bell Potter and Patersons respectively

18 February 2016 HALF YEAR REPORT 2015-2016 For a copy of the Half Year Report 2015-16, please click on the following link – Half Year Report 2015-16